Total Assets
Traded Value$Novo Nordisk AS(NVO.US) is too weak, the market is never wrong. Last year it was neck and neck with Eli Lilly, one at 60 million and the other at 70 million, but now the difference is like heaven and earth. Cheap? Munger was absolutely right—buy good companies, not cheap companies.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments